Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational therapeutic consists of exosomes (extracellular vesicles) derived from mesenchymal stem cells (MSCs), specifically being evaluated for the treatment of severe COVID-19 pneumonia. These nanoparticles, ranging from 40 to 150 nm in diameter, carry a cargo of bioactive molecules including proteins, lipids, and nucleic acids that possess anti-inflammatory and regenerative properties. The therapy is designed to modulate the immune system's response, potentially preventing the fatal cytokine storm associated with severe SARS-CoV-2 infection, and to stimulate the repair of damaged lung tissue. Developed by the Samara Regional Medical Center Dinasty, the treatment is administered via aerosol inhalation to provide direct delivery to the respiratory tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesenchymal stem cell-derived exosomes (Samara Regional Medical Center Dinasty).